Data gathered: February 23
AI Stock Analysis - Crispr Therapeutics (CRSP)
Analysis generated February 22, 2025. Powered by Chat GPT.
Crispr Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases. Based on CRISPR/Cas9 technology, the company pioneers next-generation gene-editing platforms aimed at curing genetic disorders. The wide application of CRISPR technology in healthcare can revolutionize how diseases are treated, making Crispr Therapeutics a potential game changer in the biotech industry.
Stock Alerts - Crispr Therapeutics (CRSP)
 |
Crispr Therapeutics | February 22 Insider Alert: Kulkarni Samarth is selling shares |
|
Crispr Therapeutics | February 21 Price is down by -5.8% in the last 24h. |
|
Crispr Therapeutics | February 20 Price is down by -6.5% in the last 24h. |
|
Crispr Therapeutics | February 20 Insider Alert: Bruno Julianne is selling shares |
Alternative Data for Crispr Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 97,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | 19 | Sign up | Sign up | Sign up |
| Patents | 194 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 46 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 39,206 | Sign up | Sign up | Sign up |
| Twitter Followers | 22,421 | Sign up | Sign up | Sign up |
| Twitter Mentions | 28 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 43 | Sign up | Sign up | Sign up |
| Business Outlook | 46 | Sign up | Sign up | Sign up |
| Linkedin Employees | 440 | Sign up | Sign up | Sign up |
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
| Price | $47.91 |
| Target Price | Sign up |
| Volume | 2,660,000 |
| Market Cap | $4.11B |
| Year Range | $38.36 - $62.75 |
| Dividend Yield | 0% |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
Vontobel Holding Ltd. Trims Position in CRISPR Therapeutics AG (NASDAQ:CRSP)February 20 - ETF Daily News |
 |
Citigroup Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $82.00February 19 - ETF Daily News |
|
Valeo Financial Advisors LLC Reduces Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)February 19 - ETF Daily News |
|
CRISPR Therapeutics Target of Unusually Large Options Trading (NASDAQ:CRSP)February 19 - ETF Daily News |
|
Brokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) Target Price at $74.50February 18 - ETF Daily News |
|
CRISPR Therapeutics (CRSP) Expected to Announce Quarterly Earnings on WednesdayFebruary 17 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 36M | 18M | 18M | -37M | -60M | -0.440 |
| Q3 '24 | 600,000 | 17M | -17M | -86M | -105M | -1.010 |
| Q2 '24 | 520,000 | 19M | -19M | -126M | -146M | -1.490 |
| Q1 '24 | 500,000 | 18M | -17M | -117M | -136M | -1.430 |
| Q4 '23 | 201M | 16M | 185M | 89M | 74M | 1.100 |
Insider Transactions View All
| Bruno Julianne filed to sell 7,062 shares at $52.8. February 19 '25 |
| Kulkarni Samarth filed to sell 189,973 shares at $52.8. February 19 '25 |
| KASINGER JAMES R. filed to sell 74,880 shares at $52.8. February 19 '25 |
| Kulkarni Samarth filed to sell 171,613 shares at $55.2. February 21 '25 |
| KASINGER JAMES R. filed to sell 73,002 shares at $53.9. February 19 '25 |
Similar companies
Read more about Crispr Therapeutics (CRSP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Crispr Therapeutics?
The Market Cap of Crispr Therapeutics is $4.11B.
What is the current stock price of Crispr Therapeutics?
Currently, the price of one share of Crispr Therapeutics stock is $47.91.
How can I analyze the CRSP stock price chart for investment decisions?
The CRSP stock price chart above provides a comprehensive visual representation of Crispr Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Crispr Therapeutics shares. Our platform offers an up-to-date CRSP stock price chart, along with technical data analysis and alternative data insights.
Does CRSP offer dividends to its shareholders?
As of our latest update, Crispr Therapeutics (CRSP) does not offer dividends to its shareholders. Investors interested in Crispr Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Crispr Therapeutics?
Some of the similar stocks of Crispr Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.